Insilico Medicine advances AI-discovered ISM9528, a first-in-class non-opioid pain candidate targeting a novel mechanism after promising preclinical efficacy and safety.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
Insilico Medicine has nominated ISM9528 as a preclinical candidate compound (PCC) for pain management, bringing an AI-discovered, brain-penetrant, non-opioid therapy targeting a previously undisclosed biological mechanism one step closer to clinical development. The nomination comes amid growing industry and regulatory efforts to expand the development of non-opioid pain therapies in response to the continuing public health burden of opioid dependence.
The nomination marks Insilico’s 31st preclinical candidate since 2021, further highlighting the company’s growing track record of applying generative artificial intelligence to accelerate drug discovery. The company plans to advance ISM9528 into clinical trials in 2027.
AI Identifies a Novel Biological Target for Chronic Pain
Chronic pain affects more than 20% of the global population and remains a major therapeutic challenge, particularly neuropathic pain driven by central sensitization. Current treatment options, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), often provide inadequate relief or carry significant risks such as gastrointestinal toxicity, dependence, and addiction.
The search for novel non-opioid therapies has intensified in recent years as researchers explore new biological pathways capable of providing effective analgesia without the risks associated with opioid use.
To identify new treatment opportunities, Insilico used its PandaOmics AI platform to analyze large-scale omics, scientific literature, and multimodal datasets. The analysis identified Target Z, an undisclosed biological target not previously associated with pain management, as a promising therapeutic mechanism.
Follow-up bioinformatics studies showed high expression of the target in pain-related cell types across both human and animal datasets, supporting further laboratory validation. Researchers subsequently confirmed the target’s therapeutic potential in animal models before advancing compound optimization.
Generative AI Produced an Oral, Brain-Penetrant Lead Candidate
Following target validation, Insilico applied its Chemistry42 generative chemistry platform to optimize molecules for brain penetration, selectivity, safety, and pharmacokinetic performance.
After multiple rounds of AI-driven molecular design combined with experimental validation, ISM9528 emerged as the lead candidate. The compound features a novel chemical structure and inhibits Target Z through a previously unexplored biological pathway, positioning it as a potential first-in-class therapy.
Although investment in non-opioid pain therapies has accelerated, relatively few candidates targeting entirely new biological mechanisms have advanced through clinical development. ISM9528 therefore adds to a growing pipeline of mechanistically distinct analgesic candidates.
Preclinical Studies Show Strong Analgesic Activity
In preclinical testing, ISM9528 demonstrated robust analgesic activity in validated models of acute postsurgical pain and neuropathic pain following oral administration, with efficacy matching or exceeding standard therapies depending on the model.
In the Spinal Nerve Ligation (SNL) rat model, ISM9528 restored mechanical allodynia in a dose-dependent manner. The intermediate dose produced significant analgesic effects for up to six hours after dosing and performed comparably to pregabalin at a similar dose level.
In a postsurgical acute pain model, ISM9528 also produced dose-dependent pain relief with a faster onset of action. Analgesic activity was observed as early as 30 minutes after dosing, outperforming an equivalent dose of pregabalin.
Comprehensive in vitro and in vivo safety evaluations across multiple animal models showed a favorable safety profile. The candidate also demonstrated rapid systemic absorption, efficient blood-brain barrier penetration, and promising drug metabolism and pharmacokinetic (DMPK) characteristics.
Executives Highlight AI Platform Reproducibility
Alex Zhavoronkov, PhD, Founder, Chief Executive Officer, and Chief Business Officer of Insilico Medicine, said the candidate represents one of the company’s most notable AI-enabled discoveries, citing preclinical findings showing a non-opioid therapy outperforming morphine in experimental pain models. He added that the program demonstrates how AI can uncover previously unrecognized biological mechanisms for complex diseases while supporting broader efforts to better understand aging biology.
Feng Ren, PhD, Co-Chief Executive Officer and Chief Scientific Officer, said ISM9528 combines a novel mechanism of action with a distinct chemical scaffold, strong efficacy, favorable safety findings, and promising brain-penetrant properties. He added that continued integration of generative AI and laboratory automation is improving the efficiency and reproducibility of early-stage drug discovery.
Clinical Development Planned for 2027
Senior Vice President for Clinical Development, Non-Oncology, Carol Satler, MD, PhD, said the company intends to rapidly advance ISM9528 toward first-in-human clinical studies in 2027 to address the substantial unmet need for effective non-opioid pain therapies.
If clinical studies confirm the encouraging preclinical findings, ISM9528 could join a growing wave of next-generation non-opioid analgesics that aim to expand treatment options for acute and chronic pain while reducing reliance on opioid therapies.
Insilico reports that its AI-driven discovery platform has reduced the typical timeline for preclinical candidate nomination from approximately 2.5 to 4 years to 12 to 18 months, while requiring the synthesis and testing of only 60 to 200 molecules per program. Since 2021, the company has nominated 31 preclinical candidates, 13 of which have already received Investigational New Drug (IND) approval or regulatory clearance. ISM9528 now becomes the latest addition to that pipeline as the company prepares for clinical development in 2027.
Reference
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.